StockNews.AI
ORGO
StockNews.AI
134 days

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

1. ORGO to announce Q1 2025 financial results on May 8th. 2. Management will host a conference call post-results. 3. Company focuses on regenerative medicine and advanced wound care.

Earnings
-4.88%Current Return
VS
-1.57%S&P 500
$3.8904/07 04:07 PM EDTEvent Start
$3.704/08 09:21 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings announcement usually has mixed reactions; previous reports demonstrated volatility.

How important is it?

Investor focus on upcoming Q1 results may lead to short-term price fluctuations.

Why Short Term?

Earnings reports typically influence immediate stock performance; eyes will be on Q1 results.

Related Companies

VRTXAZNAMGN
CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Related News